Listed

Enveric Biosciences, Inc.: Form 10-K for the period ended Dec 31, 2013

Filed with the SEC on Mar 28, 2014 and accepted by EDGAR at Mar 27, 2014, 17:45 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2013-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Operating income12 months2013-01-01 to 2013-12-31−$27.2kus-gaap:OperatingIncomeLoss
Income tax12 months2013-01-01 to 2013-12-31$1.4kus-gaap:IncomeTaxExpenseBenefit
Net income12 months2013-01-01 to 2013-12-31−$161us-gaap:NetIncomeLoss
Diluted EPS12 months2013-01-01 to 2013-12-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2013-01-01 to 2013-12-31−$21.6kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2013-12-31$249us-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2013-12-31$4.5kus-gaap:AssetsCurrent
Total assetsAt period end2013-12-31$4.5kus-gaap:Assets
Current liabilitiesAt period end2013-12-31$24.7kus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2013-12-31−$20.2kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001248915-14-000061. Last ingested by Listed: Nov 14, 2026, 20:02 ET. Listed shows no prices and gives no investment advice.